[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Turn Bristol-Myers Squibb into an Income Machine with This Options Play

With markets coming in to a volatile time of year, investors might be more interested in generating income rather than capital gains. 

Bristol-Myers Squibb (BMY) has long been a staple of dividend investors and with the stock showing a low Beta of 0.22 and a high yield of 3.90%, it provides an attractive opportunity for savvy investors.

Fundamentals

See More
  • Market Capitalization, $K 133,736,552
  • Shares Outstanding, K 2,042,715
  • Annual Sales, $ 48,194 M
  • Annual Income, $ 7,054 M
  • EBIT $ 14,442 M
  • EBITDA $ 18,453 M
  • 60-Month Beta 0.22
  • Price/Sales 2.87
  • Price/Cash Flow 8.12
  • Price/Book 6.05

Options Overview Details

View History
  • Implied Volatility 26.38% (-1.64%)
  • Historical Volatility 28.85%
  • IV Percentile 18%
  • IV Rank 28.77%
  • IV High 40.88% on 11/19/25
  • IV Low 20.52% on 12/31/25
  • Expected Move (DTE 7) 1.82 (2.78%)
  • Put/Call Vol Ratio 0.23
  • Today's Volume 25,877
  • Volume Avg (30-Day) 31,854
  • Put/Call OI Ratio 0.91
  • Today's Open Interest 767,922
  • Open Int (30-Day) 697,850
  • Expected Range 63.65 to 67.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $1.68
  • Number of Estimates 9
  • High Estimate $1.75
  • Low Estimate $1.59
  • Prior Year $1.63
  • Growth Rate Est. (year over year) +3.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.45 +8.83%
on 07/23/26
68.64 -4.15%
on 08/19/26
+4.86 (+7.98%)
since 07/21/26
3-Month
53.44 +23.11%
on 06/18/26
68.64 -4.15%
on 08/19/26
+6.24 (+10.48%)
since 05/21/26
52-Week
42.52 +54.73%
on 10/29/25
68.64 -4.15%
on 08/19/26
+17.36 (+35.85%)
since 08/21/25

Most Recent Stories

More News
Turn Bristol-Myers Squibb into an Income Machine with This Options Play

With markets coming in to a volatile time of year, investors might be more interested in generating income rather than capital gains.

BMY : 65.47 (unch)
1 Momentum Stock on Our Buy List and 2 We Turn Down

1 Momentum Stock on Our Buy List and 2 We Turn Down

BRC : 90.73 (unch)
CATY : 62.42 (-0.14%)
BMY : 65.47 (unch)
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory...

BMY : 65.47 (unch)
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

SAN DIEGO , Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics...

RNA : 13.48 (-1.68%)
BMY : 65.47 (unch)
Redwire Takes Off on Solid Q2 Results. How to Play RDW Stock Here.

The space company reported record revenues and a double beat, and its potential looks astronomical.

RDW : 12.03 (+2.17%)
SPCX : 135.35 (+1.01%)
BMY : 65.47 (unch)
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas

New State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Next-Generation Medicines Investment Furthers BMS’ $40 Billion Commitment...

BMY : 65.47 (unch)
1 Profitable Stock with Impressive Fundamentals and 2 We Avoid

1 Profitable Stock with Impressive Fundamentals and 2 We Avoid

JKHY : 165.08 (+1.24%)
WWW : 20.45 (-1.92%)
BMY : 65.47 (unch)
Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions

Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions

BMY : 65.47 (unch)
The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today

Bristol-Myers stock extends gains on reports of a potential merger with AstraZeneca. But caution is warranted in chasing the momentum in BMY shares today.

AZN : 164.11 (-0.23%)
BMY : 65.47 (unch)
Stocks Set to Open Higher as Oil Sinks on U.S.-Iran Deal Hopes, Jobs Data and Earnings Awaited

September S&P 500 E-Mini futures (ESU26) are up +0.57%, and September Nasdaq 100 E-Mini futures (NQU26) are up +0.47% this morning, pointing to a higher open on Wall Street as oil prices sank after U.S....

GOOGL : 343.33 (+0.78%)
UAL : 113.75 (+1.83%)
AAPL : 311.97 (+0.22%)
SNDK : 1,620.00 (+1.21%)
NQU26 : 29,477.75 (+0.60%)
PFE : 27.77 (-0.07%)
SHOP : 148.50 (+0.90%)
MSFT : 482.80 (+0.34%)
TSLA : 349.99 (+1.41%)
FERG : 239.44 (-1.54%)
WDC : 475.24 (+1.32%)
ESU26 : 7,694.00 (+0.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 68.95
2nd Resistance Point 68.24
1st Resistance Point 66.86
Last Price 65.47
1st Support Level 64.77
2nd Support Level 64.06
3rd Support Level 62.68

See More

52-Week High 68.64
Last Price 65.47
Fibonacci 61.8% 58.66
Fibonacci 50% 55.58
Fibonacci 38.2% 52.50
52-Week Low 42.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.